GRANT INCOME

9 Months Ended

Sep. 30, 2020

GRANT INCOME

GRANT INCOME

NOTE 13: GRANT INCOME

During the nine months ended September 30, 2020, the Company received $0.5 million of a grant awarded to the Mayo Foundation from the U.S. Department of Defense to fund the Phase 2 clinical trial of TPIV100 for the treatment of HER2/neu breast cancer. The portion of the grant the Company received compensated the Company for clinical supplies manufactured by the Company for the clinical trial. In accordance with Accounting Standards Update No. 2014-09, "Revenue from Contracts with Customers (Topic 606)" issued by the Financial Accounting Standards Board, the Company recorded the $0.5 million of grant income as revenue. The Company did not record any grant income during the nine months ended September 30, 2019.